ArticleThe oncologist2011
Survival of patients with chronic myelocytic leukemia: comparisons of estimates from clinical trial settings and population-based cancer registries.
Article in The oncologist, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Outcomes among pediatric patients with cancer who are treated on trial versus off trial: A matched cohort study.Cancer · 2020Trial
- Outcome of Patients Treated Within and Outside a Randomized Clinical Trial on Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: Extrapolation of a Randomized Clinical Trial (CROSS).Annals of surgical oncology · 2018Trial
- The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study.BMC cancer · 2018Article
- Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications.Blood advances · 2018Article
- Treatment outcome in a population-based, 'real-world' cohort of patients with chronic myeloid leukemia.Haematologica · 2017Article
- Trends in survival of chronic lymphocytic leukemia patients in Germany and the USA in the first decade of the twenty-first century.Journal of hematology & oncology · 2016Article
- Article
- The role of observational studies in optimizing the clinical management of chronic myeloid leukemia.Therapeutic advances in hematology · 2015Review
- Article
- Survival of adults with acute lymphoblastic leukemia in Germany and the United States.PloS one · 2014Article
- Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century.Journal of hematology & oncology · 2013Article
- Article
- Characteristics of advanced cancer patients with cancer-related fatigue enrolled in clinical trials and patients referred to outpatient palliative care clinics.Journal of pain and symptom management · 2013Article
- Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia.Cancer · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe survival of patients with chronic myelocytic leukemia (CML) has improved during the past decades. However, there have been discrepancies between results reported from clinical trials and population-based studies. We aimed to elucidate the extent of these discrepancies.
methodsWe examined the 5-year survival rate of patients in clinical trials of CML treatment and compared these results with the survival of patients in the general population using the Surveillance, Epidemiology, and End Results (SEER) database, correcting for differences in the age structure of the patient populations.
resultsTwenty-nine trials were identified for data extraction. The survival rate calculated from SEER data was lower than the survival rate in clinical trials in the corresponding period, with differences of 2.1%-50.7%. Age-adapted survival was similar for four trials, but differences up to 35.8% were seen in most. Limitations of the study include the lack of information on chemotherapy in the SEER database and possible heterogeneity of cases. DISCUSSION: The survival rate in clinical trials of CML treatment is higher than the survival rate of all patients with CML. We speculate that the difference may be a result of access to better medications, selection of healthier patients for trials, and the time necessary for adoption of new treatments. This finding underscores the need for population-based studies to give a more realistic idea of survival for patients with a given malignancy in the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.